176 related articles for article (PubMed ID: 33543891)
1. Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options.
Escobar CM; Falk KN; Mehta S; Hall EF; Menhaji K; Sappenfield EC; Brown OE; Ringel NE; Chang OH; Tellechea LM; Barnes HC; Jeney SES; Bennett AT; Cardenas-Trowers OO
Obstet Gynecol; 2021 Mar; 137(3):454-460. PubMed ID: 33543891
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
Welk B; McArthur E
BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
[TBL] [Abstract][Full Text] [Related]
3. Current and future pharmacotherapy for treating overactive bladder.
Thiagamoorthy G; Cardozo L; Robinson D
Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists.
Okui N
World J Urol; 2019 Nov; 37(11):2459-2466. PubMed ID: 30687908
[TBL] [Abstract][Full Text] [Related]
5. Persistence and compliance with medication management in the treatment of overactive bladder.
Kim TH; Lee KS
Investig Clin Urol; 2016 Mar; 57(2):84-93. PubMed ID: 26981589
[TBL] [Abstract][Full Text] [Related]
6. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
Thiagamoorthy G; Giarenis I; Cardozo L
Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
[TBL] [Abstract][Full Text] [Related]
7. [Comprehensive pharmacologic management of overactive bladder].
Krivoborodov GG; Tur EI
Urologiia; 2017 Apr; (1):82-88. PubMed ID: 28394529
[TBL] [Abstract][Full Text] [Related]
8. Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review.
Dmochowski RR; Newman DK; Rovner ES; Zillioux J; Malik RD; Ackerman AL
Adv Ther; 2023 Nov; 40(11):4741-4757. PubMed ID: 37725308
[TBL] [Abstract][Full Text] [Related]
9. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
Giarenis I; Robinson D; Cardozo L
Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339
[TBL] [Abstract][Full Text] [Related]
10. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
11. The cognitive effect of anticholinergics for patients with overactive bladder.
Welk B; Richardson K; Panicker JN
Nat Rev Urol; 2021 Nov; 18(11):686-700. PubMed ID: 34429535
[TBL] [Abstract][Full Text] [Related]
12. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
15. [Rationale of efficiency and safety of using beta3-adrenergic receptor agonist for treatment of overactive bladder].
Gadzhieva ZK; Atamanova EA
Urologiia; 2019 Sep; (4):116-121. PubMed ID: 31535817
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service.
Nazir J; Posnett J; Walker A; Odeyemi IA; Hakimi Z; Garnham A
J Med Econ; 2015 May; 18(5):390-7. PubMed ID: 25488631
[TBL] [Abstract][Full Text] [Related]
18. Inequities in Filled Overactive Bladder Medication Prescriptions in the US.
Luchristt D; Bretschneider CE; Kenton K; Simon M; Brown O
JAMA Netw Open; 2023 May; 6(5):e2315074. PubMed ID: 37223899
[TBL] [Abstract][Full Text] [Related]
19. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.
Andersson KE; Martin N; Nitti V
J Urol; 2013 Oct; 190(4):1173-80. PubMed ID: 23458471
[TBL] [Abstract][Full Text] [Related]
20. SUFU white paper on overactive bladder anticholinergic medications and dementia risk.
Zillioux J; Welk B; Suskind AM; Gormley EA; Goldman HB
Neurourol Urodyn; 2022 Nov; 41(8):1928-1933. PubMed ID: 36066046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
